Completed PHASE2 INTERVENTIONAL 1-arm NCT01756989

ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors

Sponsor: Helsinki University Central Hospital

Interventions Thalidomide, etoposide, celecoxib

Updated 5 times since 2017 Last updated: May 7, 2014 Started: Jan 31, 2005 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Brainstem Glioma and is currently completed. Helsinki University Central Hospital leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Helsinki University Central Hospital
Kuopio University Hospital
Oulu University Hospital
Tampere University Hospital
Turku University Hospital

Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland